Endometrial cancer state of the science meeting

International Journal of Gynecological Cancer

Volumn 19, Issue 1, 2009, Pages 134-140

  Kitchener, Henry C ^a   Trimble, Edward L ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trials; Endometrial cancer; Translational research

Indexed keywords

ANASTROZOLE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; GESTAGEN; LAPATINIB; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL; PACLITAXEL; PLATINUM; PROGESTERONE; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ADJUVANT THERAPY; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CARDIOTOXICITY; CLEAR CELL CARCINOMA; CYSTADENOMA; DIAGNOSTIC IMAGING; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL CANCER; HORMONAL THERAPY; HUMAN; HYSTEROSCOPY; KNOWLEDGE; LYMPHADENECTOMY; METASTASIS; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; REVIEW; SCIENCE; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TUMOR BIOPSY; ULTRASOUND; UNITED KINGDOM; UTERINE CARCINOSARCOMA; UTERUS CARCINOMA; UTERUS SARCOMA; CLINICAL TRIAL; CONFERENCE PAPER; ENDOMETRIUM TUMOR; FEMALE;

CLINICAL TRIALS AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 65649117699     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181995f90     Document Type: Review

References (33)

1. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783-4791.
2. Baak JP, Mutter GL, Robboy W, et al. The molecular genetics and morphometry-based endometrial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. 2005;103:2304-2312.
3. Yong WF, Cheung TH, Lo KW, et al. Identification of molecular markers and signalling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene. 2007;26:1971-1978.
4. Gehrig PA. Uterine papillary serous carcinoma: a review. Expert Opin Pharmacother. 2007;8:809-816.
5. Lax SF. Molecular genetic changes in epithelial, stromal, and mixed neoplasms of the endometrium. Pathology. 2007;39:46-54.
6. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer. (in press).
7. Leslie KK, Stein MP, Kumar NS, et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol. 2005;96:32-41.
8. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:4-9.
9. Morales L, Timmerman D, Neven P, et al. Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients. Int J Gynecol Cancer. 2006;16:Suppl 2:515-517.
10. Akin O, Mironov S, Pandi-Taskar N, et al. Imaging of uterine cancer. Radiol Clin North Am. 2007;45:167-182.
11. Ortashi O, Jain S, Emannuel O, et al. Evaluation of the sensitivity, specificity, positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer: a prospective study of 100 cases at the Dorset Cancer Centre. Eur U Obstet Gynecol Reprod Biol. (in press).
12. Chao A, Chang TC, Ng KK, et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging. 2006;33:36-44.
13. Mariani A, Dowdy SC, Keeney GL, et al. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol. 2004;95:120-126.
14. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
15. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Lancet. 2000;355:1404-1411.
16. Mariani A,Webb M, Keeney G, et al. Role of wide/radical hysterectomy and pelvic node dissection in endometrial cancer with cervical involvement. Gynaecol Oncol. 2001;83:72-80.
17. Chan JK, Urban R, Cheung MK, et al. Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer. 2007;109:2454-2460.
18. Holub, Jabor A, Kliment L. Comparison of two procedures of sentinel lymph node detection in patients with endometrial cancer: a pilot study. E J Gyne Oncol. 2002;23(1):L53YL57.
19. Altgassen C, Pagenstecher J, Hornung D, et al. A new approach to label sentinel nodes in endometrial cancer. Gynaecol Oncol. 2007;105:457-461.
20. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980; 56:419-427.
21. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95:266-271.
22. Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/ paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006;103:155-159.
23. Martinez AA, Weiner S, Podratz K, et al. Improved outcome at ten years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gyn Oncol. 2003;90:537-546.
24. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36-44.
25. Small W, Erickson B, Kwakwa F. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy. Int J Radiat Oncol Biol Phys. 2005:63:1502-1507.
26. Fleming GF. Systematic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007;25:2983-2990.
27. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744.
28. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10-14.
29. Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000; 78:212-216.
30. Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markersVa study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14:650-658.
31. Martin-Hirsch PL, Jarvis G, Kitchener H, et al. Progestagens for endometrial cancer. Cochrane Database Syst Rev. 2000;(2):CD001040.
32. Chen ML, Xu PZ, Peng XD, et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten T mice. Genes Dev. 2006;20(12):1569-1574.
33. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten T mice. Proc Natl Acad Sci U S A. 2001;98(18): 10320-10325.